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Abstract We are not aware of any study examining the ef-
fects of long term vitamin D administration on regression and
metabolic status of patients with cervical intraepithelial neo-
plasia grade 1 (CIN1). This study was performed to evaluate
the effects of long-term vitamin D administration on regres-
sion and metabolic status of patients with CIN1. This random-
ized, double-blind, placebo-controlled trial was performed
among 58 women diagnosed with CIN1. CIN1 diagnosis
was performed based on specific diagnostic procedures of
biopsy, pathological diagnosis, and colposcopy. Patients were
randomly allocated into two groups to take 50,000 IU vitamin
D3 supplements (n = 29) or placebo (n = 29) every 2 weeks for
6 months. Fasting blood samples were taken at the beginning
of the study and end-of-trial to measure related markers. After
6 months of vitamin D administration, greater percentage of
women in the vitamin D group had regressed CIN1 (84.6 vs.
53.8%, P = 0.01) than those in the placebo group. Long-term
vitamin D supplementation increased serum-25(OH) vitamin
D levels in the intervention group compared to the placebo
group (+12.3 ± 11.4 vs. -0.1 ± 3.7 ng/mL, P < 0.001). In
addition, vitamin D intake led to significant decreases in se-
rum insulin levels (−5.3 ± 7.3 vs. +2.4 ± 5.9 μIU/mL,
P < 0.001), homeostasis model of assessment-insulin resis-
tance (−1.2 ± 1.6 vs. +0.5 ± 1.2, P < 0.001), homeostatic
model assessment-Beta cell function (P = 0.005) and a signif-
icant elevation in quantitative insulin sensitivity check index
(+0.03 ± 0.04 vs. -0.007 ± 0.02, P < 0.001) compared with the
placebo group. Additionally, significant increases in plasma
nitric oxide (NO) (+15.5 ± 10.3 vs. +4.0 ± 13.4 μmol/L,
P = 0.001), total antioxidant capacity (TAC) (P = 0.04), total
glutathione (GSH) (+11.8 ± 153.5 vs. -294.2 ± 595.1 μmol/L,
P = 0.01) and a signif icant reduction in plasma
malondialdehyde (MDA) levels (−0.8 ± 1.0 vs. -
0.03 ± 1.4 μmol/L, P = 0.03) were observed following the
administration of vitamin D supplements compared with the
placebo group. In conclusion, vitamin D3 administration for
6 months among women with CIN1 resulted in its regression
and had beneficial effects on markers of insulin metabolism,
plasma NO, TAC, GSH and MDA levels.
Clinical trial registration number www.irct.ir:
IRCT201412065623N30.
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Introduction
Human papillomavirus (HPV) is a primary cause for cervical
cancer [1] and previous studies have proven HPV vaccine
efficacy in preventing cervical intraepithelial neoplasia
(CIN) [2]. HPV-induced CIN is a pre-cancerous condition
before formation of cervical cancer, usually cervical squa-
mous cell carcinoma (SCC), which is the second most com-
mon cancer in women worldwide [3]. A link between meta-
bolic profiles, biomarkers of inflammation, oxidative stress,
and CIN has been documented. Increased circulating levels of
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VLDL-cholesterol in patients with CIN supports the probabil-
ity of abnormal lipid metabolism in response to tissue injury in
CIN [4]. Clinical studies have also shown that the genital tract
concentrations of inflammatory factors would result in higher
cervicovaginal HPV-1 RNA concentrations in CIN [5].
Data on the relation between nutritional factors especially
vitamin D and cervical neoplasia risk are sparse and inconsis-
tent. An inverse association between dietary calcium and vi-
tamin D intake and cervical neoplasia risk was seen among a
group of Japanese women [6]. In addition, in a study by
Tworoger et al. [7] was reported that vitamin D deficiency is
associated with increased risk of ovarian cancer in overweight
and obese women. However, in another study conducted by
Arslan et al. [8] was not seen any direct association between
vitamin D deficiency and risk of ovarian cancer. Moreover, no
significant association between vitamin D deficiency and cer-
vical HPV was reported in women with systemic lupus ery-
thematosus [9].
Vitamin D intake may reduce cancer risk through modulat-
ing calcium metabolism, inhibiting cellular proliferation, in-
ducing differentiation and apoptosis [10, 11]. However, these
findings might suggest the role of vitamin D in the process of
malignant transformation and proliferation in cervical carci-
nogenesis. Therefore, we hypothesized that metabolic profile
of CIN patients might be improved by vitamin D supplemen-
tation. We are not aware of any study evaluating the effects of
vitamin D administration on regression, glucose homeostasis
parameters, lipid concentrations, biomarkers of inflammation
and oxidative stress in patients with CIN grade 1 (CIN1). The
aim of current study was to evaluate the effects of long-term
vitamin D supplementation (6 months) on regression and met-
abolic status of women diagnosed with CIN1.
Materials and Methods
Participants
The study is a randomized double-blind clinical trial conduct-
ed in Kashan, Iran, from August 2014 to February 2015. The
inclusion criteria were women aged 18–55 years with CIN1
diagnosed by colposcopy, biopsy, and pathological assess-
ment [12]. Women who had abnormal Pap smear test, abnor-
mal cervical cytology, abnormal cervical appearance, postco-
ital bleeding, intermenstrual bleeding, and chronic vaginal
discharge, or were high risk HPV positive were invited for a
colposcopy. Exclusion criteria were: a history of cervical can-
cer or other cancer of the lower genital tract; a history of
hysterectomy; and a destructive therapy of the cervix.
Pregnant women were also excluded from the study. The cur-
rent study was conducted according to the guidelines laid
down in the Declaration of Helsinki.Written informed consent
was obtained from all participants. This trial was approved by
the ethics committee of Kashan University of Medical
Sciences and has been registered in the Iranian Registry of
Clinical Trial (www.irct.ir: IRCT201412065623N30).
Study Design
At the beginning of the study, participants were stratified ac-
cording their BMI (<30 and ≥30 kg/m2) and age (<35 and ≥35
y), then patients were randomly allocated to receive 50,000 IU
vitamin D3 supplements (n = 29) or placebo (n = 29) every
2 weeks for 6 months. We used the blocked randomization
method by a trained midwife at maternity clinic. Vitamin D
supplements and its placebos were manufactured by Zahravi
Pharmaceutical Company (Tabriz, Iran) and Barij Essence
Pharmaceutical Company (Kashan, Iran). The appearance of
the placebo pearls, including color, shape, size, and packag-
ing, were identical to vitamin D pearls. Women were advised
not to change their diet and physical activity during the study
and none of them had taken any other nutritional supplements
for at least 2 months prior to (or during) this study.
Compliance to the vitamin D administration was evaluated
through quantification of serum vitamin D concentrations.
The use of vitamin D supplements and placebos throughout
the study was also controlled through asking patients to bring
the medication containers. All patients provided three dietary
records (one weekend day and two week days) and three
physical activity records at month 2, 4 and 6 of the interven-
tion to make sure that they maintained their usual diet and
physical activity during intervention. The dietary records were
based on estimated values in household measurements. To
obtain nutrient intakes of the participants based on these 3-
day food diaries, we used Nutritionist IV software (First
Databank, San Bruno, CA) which is a modified version for
Iranian food.
Assessment of Variables
Body weight was measured once at the beginning of the study
and after 6 months of the intervention at gynecology clinics in
an overnight fasting status without shoes in a minimal clothing
state using a digital scale (Seca, Hamburg, Germany) by a
trained midwife. Height was determined using a non-
stretched tape measure (Seca, Hamburg, Germany). BMI
was calculated using the height and weight measurements
(weight in kg/[height in meters] 2). Fasting blood samples
(10 mL) were taken at the first of the study and end-of-trial
at Kashan reference laboratory in an early morning after an
overnight fast of at least 8 h. Blood samples were immediately
centrifuged (Hettich D-78532, Tuttlingen, Germany) at
3500 rpm for 10 min to separate serum. Then, the samples
were stored at −80°C until analysis at the KUMS reference
laboratory.
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Assessment of Primary Outcomes
In the current study, the primary outcome was CIN1 that were
determined through colposcopy, cervical biopsy and patho-
logical diagnosis at the study baseline and 6 months after the
intervention. To determine the location and extent of CIN, a
colposcopy was performed at enrolment for patients who had
abnormal Pap smear test, abnormal cervical cytology, abnor-
mal cervical appearance, postcoital bleeding, intermenstrual
bleeding, and chronic vaginal discharge or were HPV posi-
tive. Colposcopy (Siemens Co, Germany) was conducted with
the patient lying back, legs in stirrups, and buttocks at the
lower edge of the table (known as the dorsal lithotomy posi-
tion). A speculum was placed in the vagina after the vulva is
examined for any suspicious lesions. Areas of the cervix,
which turn dense white after the application of acetic acid or
have an abnormal vascular pattern (mosaicism and punctua-
tion), were considered for the biopsy. Specimens were embed-
ded in formalin solution and then sent for the pathological
diagnosis. Assessment of the pathological diagnosis was done
as blindness by a single experienced pathologist at baseline
and 6 months after the intervention.
Secondary Outcomes
The secondary outcomes of the current study were markers of
insulin metabolism, lipid profiles, biomarkers of inflamma-
tion, and oxidative stress. Serum 25-hydroxyvitamin D con-
centrations were assessed using a commercial ELISA kit
(IDS, Boldon, UK) with inter- and intra-assay CVs ranged
from 4.5 to 6.5%. Commercial kits were used to determine
the fasting plasma glucose (FPG), serum triglycerides,
VLDL-, total-, LDL-, and HDL-cholesterol concentrations
(Pars Azmun, Tehran, Iran). All inter- and intra-assay CVs
for FPG and lipid concentrations measurements were lower
than 5%. Serum insulin concentrations were determined by
ELISA kit (Monobind, CA, USA). The homeostatic model
of assessment for insulin resistance (HOMA-IR), homeostatic
model assessment for β-cell function (HOMA-B) and the
quantitative insulin sensitivity check index (QUICKI) were
calculated based on suggested formulas [13]. Serum high sen-
sitivity C-reactive protein (hs-CRP) was measured by ELISA
kit (LDN, Nordhorn, Germany) with intra- and inter-assay
CVs of 2.9 and 4.5%, respectively. Plasma nitrite/nitrate
(NOx), taken as an index of nitric oxide (NO) concentrations,
was quantified using the Giess method modified by Tatsh
et al. [14]. Plasma total antioxidant capacity (TAC) by the
FRAP method developed by Benzie and Strain [15], total
glutathione (GSH) using the method of Beutler et al. [16]
and malondialdehyde (MDA) concentrations by the thiobar-
bituric acid reactive substance (TBARs) spectrophotometric
test [17] were determined.
Sample Size
To determine the sample size, we used a randomized clinical
trial sample size formula where type one (α) error was con-
sidered as 5% and the study power as 80%. We considered
neoplasia as the main outcome of the study; therefore, based
on a previous study [18] and considering 20% as the differ-
ence in neoplasia between the two groups and the variability
of 5%, we needed 24 persons in each group. Assuming a
dropout of 5 subjects per group, the final sample size was
determined to be 29 subjects per group.
Statistical Methods
Normal distribution of variables was assessed by visual in-
spection of histograms. To identify between-group differences
for non-normally distributed variables, we used Mann-
Whitney test. Results of normally distributed variables as
mean ± standard deviations (SDs) and non-normally distrib-
uted variables (vitamin D, FPG, HOMA-B, hs-CRP and TAC)
as median (IQR) were presented. The analyses were conduct-
ed in all randomized subjects according to the intention-to-
treat (ITT) principle. Missing values were treated based on
Last-Observation-Carried-Forward method (LOCF) [19].
LOCF ignores whether the participant’s condition was im-
proving or deteriorating at the time of dropout but instead
freezes outcomes at the value observed before dropout (i.e.,
last observation). We used independent samples Student’s t
test to detect mean differences in baseline measures as well
as dietary intakes between the two groups. In addition, paired-
samples t-test was used to detect within-group differences.
Pearson Chi-square test was used for comparison of categor-
ical variables. To determine the effects of vitamin D supple-
mentation on markers of insulin metabolism, lipid concentra-
tions, biomarkers of inflammation and oxidative stress, we
used one-way repeated measures analysis of variance. To as-
sess if the magnitude of the change before and after the inter-
vention depended on the baseline values, we adjusted all anal-
yses for the baseline values, including age and baseline BMI,
to avoid the potential bias that might have resulted. These
analyses were also performed using analysis of covariance
(ANCOVA). P < 0.05 was considered as statistically signifi-
cant. All statistical analyses were done using the Statistical
Package for Social Science version 17 (SPSS Inc., Chicago,
Illinois, USA).
Results
Six patients did not complete the trial [vitamin D (n = 3) and
placebo (n = 3)]. Therefore, a total of 52 participants [vitamin
D (n = 26) and placebo (n = 26)] completed the trial (Fig. 1).
However, as the analysis was done based on ITT principle, all
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58 patients were included in the final analysis. On average, the
rate of compliance in the current study was high, such that
>90% of tablets were taken throughout the study in both
groups. No side effects were reported following the adminis-
tration of vitamin D supplements or placebo throughout the
study.
Mean age and height of participants were not statistically
different between vitamin D and placebo groups. Baseline
weight and BMI as well as their means before and after
6 months of intervention were not significantly different be-
tween the two groups (Table 1). In addition, after 6 months of
vitamin D supplementation, greater percentage of women in
the vitamin D group had regressed CIN1 than those in the
placebo group (84.6 vs. 53.8%, P = 0.01). Meanwhile, one
patient in the placebo group converted to CIN-П.
Based on the 3-day dietary records obtained throughout the
intervention, no significant differences were observed be-
tween the two groups in intakes of energy, carbohydrate, pro-
tein, fat, saturated fatty acids (SFA), polyunsaturated fatty
acids (PUFA), monounsaturated fatty acids (MUFA), choles-
terol, total dietary fiber (TDF), vitamin D, calcium and phos-
phors (Table 2).
Long-term vitamin D supplementation increased serum-
25(OH) vitamin D levels in the intervention group compared
to the placebo group (+12.3 ± 11.4 vs. -0.1 ± 3.7 ng/mL,
P < 0.001) (Table 3). Comparedwith the placebo group, wom-
en in vitamin D supplementation group had a significant de-
crease in serum insulin levels (−5.3 ± 7.3 vs. +2.4 ± 5.9 μIU/
mL, P < 0.001), HOMA-IR (−1.2 ± 1.6 vs. +0.5 ± 1.2,
P < 0.001), HOMA-B (P = 0.005) and a significant elevation
Randomized (n=58) 
Allocated to placebo (n=29) 
Lost to follow-up due to 
personal reasons (n=3) 
Analyzed (n=29) 
Allocated to intervention (n=29) 
Lost to follow-up due to personal 
reasons (n=3) 
Analyzed (n=29) 
Assessed for eligibility (n=70) 
Excluded (n=12)  
























Fig. 1. Summary of patient flow
diagram
Table 1 General characteristics





Age (years) 38.5 ± 8.3 36.9 ± 7.4 0.43
Height (cm) 159.5 ± 6.6 158.6 ± 4.3 0.55
Weight at study baseline (kg) 75.0 ± 15.9 68.1 ± 9.5 0.05
Weight at end-of-trial (kg) 74.9 ± 16.1 68.9 ± 9.5 0.11
Weight change (kg) -0.1 ± 1.6 0.8 ± 1.4 0.02
BMI at study baseline (kg/m2) 29.5 ± 6.5 27.2 ± 4.2 0.10
BMI at end-of-trial (kg/m2) 29.4 ± 6.4 27.5 ± 4.2 0.16
BMI change (kg/m2) -0.1 ± 0.6 0.3 ± 0.5 0.02
CIN1 regression (%) 14 (53.8) † 22 (84.6)† 0.01††
1 Data are means ± SDs
2Obtained from independent t test
†Analysis was done on 26 patients. Three persons due to withdrawn were excluded
††Obtained from Pearson Chi-square test
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in QUICKI score (+0.03 ± 0.04 vs. -0.007 ± 0.02, P < 0.001).
Additionally, significant increases in plasma NO
(+15.5 ± 10.3 vs. +4.0 ± 13.4 μmol/L, P = 0.001), TAC
(P = 0.04), GSH (+11.8 ± 153.5 vs. -294.2 ± 595.1 μmol/L,
P = 0.01) and a significant reduction in MDA levels
(−0.8 ± 1.0 vs. -0.03 ± 1.4 μmol/L, P = 0.03) were observed
following the administration of vitamin D supplements com-
pared with the placebo group. However, analysis was done
without ITT approach and no significant change was seen in
our findings.
Table 2 Dietary intakes of study





Energy (kcal/d) 2394 ± 227 2352 ± 299 0.55
Carbohydrates (g/d) 329.7 ± 39.1 328.5 ± 60.6 0.92
Protein (g/d) 85.9 ± 14.7 86.4 ± 18.5 0.90
Fat (g/d) 85.0 ± 12.7 80.7 ± 16.8 0.27
SFA (g/d) 24.7 ± 4.8 25.0 ± 5.6 0.81
PUFA (g/d) 25.5 ± 6.4 25.5 ± 7.1 0.98
MUFA (g/d) 23.7 ± 6.9 22.6 ± 6.8 0.55
Cholesterol (mg/d) 224.8 ± 121.7 194.7 ± 105.1 0.31
TDF (g/d) 19.7 ± 5.2 19.2 ± 4.8 0.68
Vitamin D (μg/d) 2.8 ± 0.9 2.8 ± 0.8 0.93
Calcium (mg/d) 1141.3 ± 213.6 1117.1 ± 175.3 0.64
Phosphors (mg/d) 1159.8 ± 199.2 1159.8 ± 207.4 0.65
1Data are means ± SDs
2Obtained from independent t test
SFA, saturated fatty acid; PUFA, polyunsaturated fatty acid; MUFA, monounsaturated fatty acid; TDF, total
dietary fiber
Table 3 Metabolic profiles, biomarkers of inflammation and oxidative stress at study baseline and after 6 months intervention in women with CIN1
that received either vitamin D supplements or placebo1
Placebo group (n = 29) Vitamin D group (n = 29) P2
Baseline End-of-trial Change Baseline End-of-trial Change
Vitamin D (ng/mL) 11.2 (14.7) 10.5 (13.3) -0.8 (2.7) 10.8 (13.5) 26.8 (29.1)* 14.3 (17.3) <0.001†
FPG (mg/dL) 85.0 (88.5) 84.0 (100.0) 0 (13.0) 85.0 (91.0) 80.0 (84.0) -4.0 (0) 0.08†
Insulin (μIU/mL) 12.2 ± 4.1 14.6 ± 7.0* 2.4 ± 5.9 13.5 ± 6.5 8.2 ± 4.6* -5.3 ± 7.3 <0.001
HOMA-IR 2.6 ± 1.1 3.1 ± 1.5* 0.5 ± 1.2 2.9 ± 1.4 1.7 ± 1.0* -1.2 ± 1.6 <0.001
HOMA-B 48.9 (58.1) 47.8 (81.1) 0 (36.4) 50.3 (66.0) 30.7 (51.2)* -13.2 (0.6) 0.005†
QUICKI 0.33 ± 0.02 0.32 ± 0.02 -0.007 ± 0.02 0.33 ± 0.02 0.36 ± 0.04* 0.03 ± 0.04 <0.001
Triglycerides (mg/dL) 106.2 ± 59.0 118.5 ± 52.8 12.3 ± 41.7 115.6 ± 50.3 108.6 ± 51.6 -7.0 ± 32.1 0.05
VLDL-cholesterol (mg/dL) 21.2 ± 11.8 23.7 ± 10.5 2.5 ± 8.3 23.1 ± 10.1 21.7 ± 10.3 -1.4 ± 6.4 0.05
Total cholesterol (mg/dL) 174.7 ± 30.3 174.3 ± 22.9 -0.4 ± 21.4 170.1 ± 34.6 173.2 ± 31.9 3.1 ± 20.4 0.52
LDL-cholesterol (mg/dL) 95.0 ± 19.6 92.9 ± 19.2 -2.1 ± 16.1 91.3 ± 25.8 95.8 ± 27.3 4.5 ± 18.3 0.14
HDL-cholesterol (mg/dL) 58.4 ± 9.6 57.7 ± 8.0 -0.7 ± 6.9 55.7 ± 7.6 55.7 ± 7.0 0.0 ± 5.3 0.66
hs-CRP (ng/mL) 1587.0 (4290.0) 1641.0 (4290.0) 0 (618.5) 1534.0 (3507.0) 1957.0 (3716.0) 320.1 (864.8) 0.28†
NO (μmol/L) 52.2 ± 7.2 56.2 ± 12.6 4.0 ± 13.4 43.5 ± 9.4 59.0 ± 10.7* 15.5 ± 10.3 0.001
TAC (mmol/L) 768.6 (883.9) 788.7 (956.6) 6.2 (44.1) 879.4 (1177.1) 1150.0 (1320.7)* 50.0 (339.5) 0.04†
GSH (μmol/L) 827.7 ± 598.9 533.5 ± 83.9* -294.2 ± 595.1 769.4 ± 246.2 781.2 ± 229.1 11.8 ± 153.5 0.01
MDA (μmol/L) 6.0 ± 2.1 6.0 ± 2.3 -0.03 ± 1.4 4.8 ± 1.4 4.0 ± 1.1* -0.8 ± 1.0 0.03
1Values are means ± SDs for normally distributed variables and median (IQR) for non-normally distributed variables
2 Obtained from repeated measures ANOVA test
†Obtained from Mann-Whitney test
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated insulin resistance; HOMA-B, homeostasis
model of assessment-estimated B cell function; hs-CRP, high-sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI,
quantitative insulin sensitivity check index; TAC, total antioxidant capacity
* Different from study baseline, P < 0.05
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There was a significant difference in the baseline levels of
MDA (P = 0.01) between the two groups. Therefore, we ad-
justed the analysis for baseline values of biochemical param-
eters, age, baseline BMI, and baseline levels of insulin,
VLDL-cholesterol, hs-CRP and TAC. When we adjusted the
analyses for baseline values of biochemical variables, there
was no significant change in our findings (data not shown).
In addition, when we adjusted the analysis for baseline values
of biochemical parameters, age, and baseline BMI, findings
did not alter (Table 4). When we adjusted the analysis for
baseline values of biochemical parameters, age and baseline
BMI, and baseline levels of insulin, VLDL-cholesterol, hs-
CRP, and TAC, plasma NO (P = 0.17) and MDA levels
(P = 0.13) became non-significant, while FPG (P = 0.04),
triglycerides (P = 0.04), and VLDL-cholesterol (P = 0.04)
became statistically significant, and other findings did not
alter.
Discussion
To our knowledge, the effects of vitamin D supplementation
on CIN have not been evaluated previously. The present study
for the first time demonstrated that in patients with CIN1 tak-
ing one dose of 50,000 IU vitamin D supplement every
2 weeks for 6 months compared with the placebo group re-
sulted in (1) a higher regression; (2) decreased markers of
insulin metabolism; and (3) improved biomarkers of inflam-
mation and oxidative stress such as NO, TAC, GSH, and
MDA.
Patients with CIN are susceptible to cervical cancer in a
linear fashion [20]. Previous epidemiological studies have
shown that vitamin D has various anticancer effects [21, 22];
however, the biological mechanism of vitamin D in cancer
cells remains poorly understood. Vitamin D is metabolized
to 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], which regulates
cell growth and differentiation, and immune system in various
tissues [23, 24]. Moreover, in two studies by Friedrich et al.
[25, 26], it was demonstrated that messenger RNA and protein
expression of vitamin D receptor and vitamin D activating
enzyme were increased in cervical cancer tissue compared
with normal tissues. In another study by Schulte-Uebbing
et al. [27] was seen that treatment with vitamin D vaginal
suppositories (12,500 IU, three nights a week, for 6 weeks)
resulted in antidysplastic effects in the CIN 1 group, but did
not affect in the CIN 2 group.
We found that vitamin D administration in women with
CIN led to significant reductions in serum insulin concentra-
tions, HOMA-IR, HOMA-B and a significant rise in QUICKI
score, but had no effects on FPG and lipid concentrations.
Supporting our findings, significant decrease in markers of
insulin metabolism were seen with oral vitamin D supplemen-
tation at 1250 μg/week for 8 weeks among adult males with
obesity or normal weight [28] and following the intake of
100,000 IU vitamin D3 among women with gestational dia-
betes mellitus (GDM) for 6 weeks [29]. Similarly, our previ-
ous study among pregnant women at risk of pre-eclampsia
showed a significant difference in markers of insulin metabo-
lism following the administration of 50,000 IU vitamin D
supplements every 2 weeks for 12 weeks [30]. In another
study supplementation with 150,000 IU vitamin D every
3 months for 24 weeks did not alter lipid profiles in over-
weight and obese youth [31]. However, some other studies
did not report such favorable effects of vitamin D supplemen-
tation on glucose homeostasis parameters. For example, vita-
min D supplementation with 400 IU or 2000 IU per day for
12 weeks did not affect β-cell function or insulin function in
obese nondiabetic adolescents with relatively good vitamin D
status [32]. Furthermore, similar findings were observed
among patients with type 2 diabetes mellitus (T2DM) after
24 weeks of intervention [33] and after 6 months of [34]
vitamin D supplementation. The anti-inflammatory activity
of vitamin D [35] and increased expression of the insulin
receptor and/or proteins of the insulin-signaling cascade by
vitamin D [36] may result in an important role in insulin se-
cretion and sensitivity. The absent of significant change of
vitamin D supplementation on lipid concentrations in our
study might be mediated by distinct trial designs, various dos-
ages of vitamin D supplements, and characteristics of the
participants.
The current study demonstrated that the administration of
vitamin D supplementation in women with CIN resulted in a
significant increase in plasma NO levels compared with the
placebo, but did not influence serum hs-CRP levels. In accor-
dance with our study, another study [35] also showed that NO
production notably decreased with decreasing 25(OH)D plas-
ma concentration in patients with osteoarthritis. Moreover,
vitamin D3 supplementation with doses of 1000, 2000, or
4000 IU/day orally for 3 months did not show any significant
change in CRP concentrations [37]. However, a 6-week sup-
plementation with 1000 mg calcium per day and 50,000 IU
vitamin D3 pearl two times during the study (at study baseline
and day 21 of intervention) did not alter hs-CRP and NO
concentrations among patients withGDM [38]. Recent studies
have reported that impaired generation and signaling of NO
contribute significantly to cardiovascular risk associated with
hypertension and hyperlipidemia [39]. Several studies have
shown increased inflammatory factors associated with in-
creased risk of cervical cancer development [40, 41].
Therefore, vitamin D due to their anti-inflammatory and
anti-oxidative actions may be useful to decrease the progres-
sion of CIN to cervical cancer. Accurate explanation to the
beneficial effects of vitamin D supplements on NO levels
cannot be provided, but it seems that vitamin D may affect
NO production through vitamin D receptor (VDR). In a study
by Abu El Maaty et al. [42] was reported that VDR mutant
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mice resulted in lower bioavailability of the vasodilator NO
due to reduced expression of the key NO synthesizing enzyme
and endothelial NO synthase.
The present study showed that taking vitamin D sup-
plements for 6 months was associated with a significant
rise in plasma TAC, GSH and a significant reduction in
Table 4 Adjusted changes in
metabolic variables in women
with CIN1 that received either








Model 1† -0.3 ± 1.1 12.5 ± 1.1 <0.001
Model 2†† -0.6 ± 1.2 12.8 ± 1.2 <0.001
FPG (mg/dL)
Model 1 1.8 ± 1.9 -3.5 ± 1.9 0.06
Model 2 2.2 ± 1.9 -3.9 ± 1.9 0.04
Insulin (μIU/mL)
Model 1 2.1 ± 1.1 -5.0 ± 1.1 <0.001
Model 2 2.0 ± 1.2 -5.0 ± 1.2 <0.001
HOMA-IR
Model 1 0.4 ± 0.2 -1.1 ± 0.2 <0.001
Model 2 0.5 ± 0.2 -1.1 ± 0.2 <0.001
HOMA-B
Model 1 8.8 ± 5.0 -20.6 ± 5.0 <0.001
Model 2 8.5 ± 5.3 -20.3 ± 5.3 0.001
QUICKI
Model 1 -0.007 ± 0.006 0.03 ± 0.006 <0.001
Model 2 -0.009 ± 0.007 0.03 ± 0.007 <0.001
Triglycerides (mg/dL)
Model 1 10.9 ± 6.7 -5.6 ± 6.7 0.09
Model 2 13.7 ± 7.0 -8.5 ± 7.0 0.04
VLDL-cholesterol (mg/dL)
Model 1 2.2 ± 1.3 -1.1 ± 1.3 0.09
Model 2 2.7 ± 1.4 -1.7 ± 1.4 0.04
Total cholesterol (mg/dL)
Model 1 0.1 ± 3.4 2.7 ± 3.4 0.58
Model 2 1.1 ± 3.6 1.7 ± 3.6 0.91
LDL-cholesterol (mg/dL)
Model 1 -1.9 ± 3.1 4.4 ± 3.1 0.16
Model 2 -1.2 ± 3.3 3.7 ± 3.3 0.33
HDL-cholesterol (mg/dL)
Model 1 -0.006 ± 1.0 -0.7 ± 1.0 0.62
Model 2 -0.5 ± 1.0 -0.2 ± 1.0 0.88
hs-CRP (ng/mL)
Model 1 -143.2 ± 328.5 261.7 ± 328.5 0.39
Model 2 -61.5 ± 356.5 179.9 ± 356.5 0.65
NO (μmol/L)
Model 1 6.1 ± 2.2 13.4 ± 2.2 0.03
Model 2 7.1 ± 2.4 12.4 ± 2.4 0.17
TAC (mmol/L)
Model 1 16.8 ± 35.9 183.6 ± 35.9 0.003
Model 2 3.7 ± 35.0 204.1 ± 35.1 <0.001
GSH (μmol/L)
Model 1 -272.9 ± 31.3 -9.5 ± 31.3 <0.001
Model 2 -265.2 ± 32.4 -17.1 ± 32.4 <0.001
MDA (μmol/L)
Model 1 0.003 ± 0.2 -0.8 ± 0.2 0.01
Model 2 -0.1 ± 0.2 -0.7 ± 0.2 0.13
1All values are means ± SEs
2Obtained from ANCOVA test
†Adjusted for baseline values of biochemical variables, age and baseline BMI
††Adjusted for baseline values of biochemical variables, age, baseline BMI, and baseline levels of insulin, VLDL-
cholesterol, hs-CRP and TAC
FPG, fasting plasma glucose; GSH, total glutathione; HOMA-IR, homeostasis model of assessment-estimated
insulin resistance; HOMA-B, homeostasis model of assessment-estimated B cell function; hs-CRP, high-
sensitivity C-reactive protein; MDA, malondialdehyde; NO, nitric oxide; QUICKI, quantitative insulin sensitivity
check index; TAC, total antioxidant capacity
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MDA concentrations in women with CIN compared with
the placebo. In our previous study, vitamin D and calcium
supplementation for 6 weeks prevented a rise in MDA
levels among women with GDM [38]. Another trail l also
showed a non-significant reduction in MDA levels after
vitamin D supplementation for 6 weeks among patients
with T2DM [43]. Supplementation with 50,000 IU vita-
min D3 every 14 days for 4 months among adult patients
with non-alcoholic fatty liver disease resulted in amelio-
ration in MDA concentrations but did not affect TAC
concentrations [44]. Increased bioavailability of reactive
oxygen species and free radicals has been implicated in
progression of diabetes mellitus and cardiovascular com-
plications [45]. Oxidative stress could have an important
key during the progression of neoplasias [46]. Lipid per-
oxidation and reducing levels of antioxidants were shown
to be increased in patients with high-grade squamous
intraepithelial lesion or invasive cervical cancer [47].
The increased production of oxidant compounds in CIN
may be involved in angiogenesis, leading to tumor growth
and dissemination [48]. Vitamin D intake may reduce ox-
idative stress and lipid peroxidation by induced superox-
ide dismutase activity [49] and upregulation of antioxi-
dant systems including glutathione peroxidase via its nu-
clear receptors [50].
The current study had few strengths. First of all, we
focused on interesting questions using a randomized, dou-
ble-blind, placebo-controlled trial. The findings of in-
creased regression in the vitamin D group are intriguing,
but need to be confirmed in a larger study. In addition to
looking at the primary endpoint (regression of CIN1), we
also evaluate the metabolic status of these patients and
found that there was an improvement in glucose homeo-
stasis among other metabolic parameters. To interpret our
findings, some limitations need to be taken into account.
We were unable to assess the effects of vitamin D admin-
istration on HPV. Furthermore, due to limited funding, we
did not examine the effect of supplementation on signal-
ing pathway involved in CIN. It must be kept in mind that
in the current study, at the onset of the study, participants
were stratified according their BMI (<30 and ≥30 kg/m2)
and age (<35 and ≥35 y). As increased abnormal lipid
metabolism may be present in patients with CIN1, strati-
fication of participants based on baseline circulating
VLDL-cholesterol levels is required. Therefore, this
should be taken into account in the interpretation of our
findings. In addition, stratification of participants based
on baseline circulating VLDL-cholesterol levels is sug-
gested in future studies.
In conclusion, vitamin D3 supplementation for 6 months
among women with CIN1 resulted in its regression and had
beneficial effects on glucose homeostasis parameters, plasma
levels of NO and MDA.
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